Could Long-Acting Cabotegravir-Rilpivirine Be the Future for All People Living with HIV? Response Based on Genotype Resistance Test from a Multicenter Italian Cohort

Long-acting (LA) formulations have been designed to improve the quality of life of people with HIV (PWH) by maintaining virologic suppression. However, clinical trials have shown that patient selection is crucial. In fact, the HIV-1 resistance genotype test and the Body Mass Index of individual pati...

Descripción completa

Detalles Bibliográficos
Autores principales: De Vito, Andrea, Botta, Annarita, Berruti, Marco, Castelli, Valeria, Lai, Vincenzo, Cassol, Chiara, Lanari, Alessandro, Stella, Giulia, Shallvari, Adrian, Bezenchek, Antonia, Di Biagio, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877047/
https://www.ncbi.nlm.nih.gov/pubmed/35207677
http://dx.doi.org/10.3390/jpm12020188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877047/
https://www.ncbi.nlm.nih.gov/pubmed/35207677
http://dx.doi.org/10.3390/jpm12020188

Ejemplares similares